These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30023346)

  • 1. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
    Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H
    Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib for Anaplastic Thyroid Cancer.
    Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S
    Front Oncol; 2017; 7():25. PubMed ID: 28299283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
    Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
    J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
    Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M
    Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models.
    Enomoto K; Hirayama S; Kumashiro N; Jing X; Kimura T; Tamagawa S; Matsuzaki I; Murata SI; Hotomi M
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
    Kim M; Ahn J; Song DE; Yoon JH; Kang HC; Lim DJ; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim BH
    Endocrine; 2021 Feb; 71(2):427-433. PubMed ID: 32729092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
    Lorusso L; Pieruzzi L; Biagini A; Sabini E; Valerio L; Giani C; Passannanti P; Pontillo-Contillo B; Battaglia V; Mazzeo S; Molinaro E; Elisei R
    Onco Targets Ther; 2016; 9():6467-6477. PubMed ID: 27799794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer.
    Su X; Liu J; Zhang H; Gu Q; Zhou X; Ji M; Yao D
    Onco Targets Ther; 2020; 13():11183-11192. PubMed ID: 33173310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.
    Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Nakayama H; Toda S; Masudo K
    Oncol Lett; 2018 Dec; 16(6):7271-7277. PubMed ID: 30546466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
    Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
    Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report.
    Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y
    Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
    Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
    [No Abstract]   [Full Text] [Related]  

  • 20. Histological findings of thyroid cancer after lenvatinib therapy.
    Okubo Y; Toda S; Sato S; Yoshioka E; Ono K; Hasegawa C; Washimi K; Yokose T; Miyagi Y; Iwasaki H; Hayashi H
    Histopathology; 2023 Oct; 83(4):657-663. PubMed ID: 37501641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.